Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Moxidectin is a macrocyclic lactone derived from Streptomyces bacteria, developed in the 1980s by American Cyanamid Co. It is primarily used as an antiparasitic agent in both humans and animals, acting on gamma-aminobutyric acid (GABA) and glutamate-gated channels to induce flaccid paralysis in parasites. Moxidectin is approved for treating human onchocerciasis, a filarial infection prevalent in Africa, Yemen, and parts of South America. In veterinary medicine, it is utilized for controlling heartworm, gastrointestinal nematodes, and lungworms in various animals. Structurally, moxidectin is a milbemycin, distinguishing it from other macrocyclic lactones like avermectins. Its hydrophobic nature contributes to its efficacy and widespread use in pest control. Recent studies have also explored its potential in synergizing with antifungal agents to inhibit Candida albicans biofilm formation.
仅用于科研。不用于诊断过程。未经明确授权不得转售。